Top Page
Bayer
(OTC:BAYRY)
Bayer (BAYRY) vs. SPDR S&P 500 ETF (SPY)
Bayer Business Overview & Revenue Model
Bayer Key Performance Indicators (KPIs)
Reveals the profitability of each business unit before interest, taxes, depreciation, and amortization, indicating which segments drive earnings and operational efficiency.
The FlyBayer Earnings Call Summary
Bayer Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.17B | 46.61B | 47.64B | 50.74B | 44.08B | 41.40B |
| Gross Profit | 25.37B | 25.34B | 27.89B | 30.87B | 27.27B | 22.26B |
| EBITDA | 6.55B | 8.81B | 4.21B | 10.44B | 6.97B | -11.48B |
| Net Income | -3.42B | -2.55B | -2.94B | 4.15B | 1.00B | -15.56B |
Balance Sheet | ||||||
| Total Assets | 105.24B | 110.85B | 116.26B | 124.88B | 120.24B | 117.05B |
| Cash, Cash Equivalents and Short-Term Investments | 5.50B | 8.09B | 10.59B | 10.15B | 7.74B | 11.88B |
| Total Debt | 0.00 | 40.70B | 44.79B | 41.65B | 39.53B | 41.55B |
| Total Liabilities | 74.74B | 78.81B | 83.18B | 85.95B | 87.07B | 86.35B |
| Stockholders Equity | 30.37B | 31.91B | 32.93B | 38.77B | 33.02B | 30.52B |
Cash Flow | ||||||
| Free Cash Flow | 4.59B | 4.59B | 2.37B | 4.14B | 2.48B | 2.48B |
| Operating Cash Flow | 7.15B | 7.37B | 5.12B | 7.09B | 5.09B | 4.90B |
| Investing Cash Flow | 2.78B | 164.00M | -4.01B | -2.38B | 855.00M | -4.07B |
| Financing Cash Flow | -8.89B | -7.18B | -679.00M | -4.22B | -5.64B | 423.00M |
Bayer Technical Analysis
Bayer Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $153.73B | 19.19 | 40.53% | 2.51% | 2.76% | 6407.19% | |
77 Outperform | $97.13B | 13.58 | 35.62% | 3.41% | 5.97% | 128.66% | |
77 Outperform | $143.00B | 14.66 | 10.59% | 6.73% | 4.44% | 128.96% | |
75 Outperform | $122.23B | 12.40 | 8.39% | 4.45% | -9.32% | 120.62% | |
69 Neutral | $98.23B | 16.29 | 33.84% | 4.87% | 1.26% | ― | |
64 Neutral | $39.13B | ― | -0.99% | 0.31% | -0.40% | 66.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Bayer Corporate Events
Bayer AG is launching a new clinical study titled A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Post-menarchal Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Progestin for 6 Months. The study aims to evaluate the effectiveness of Mirena, an intrauterine device, compared to oral progestins in treating nonatypical endometrial hyperplasia (NAEH) in women. This condition involves a thickening of the uterine lining and can lead to cancer if untreated, highlighting the significance of finding effective treatments.
Study Overview: Bayer AG is conducting an observational study titled ‘Special Drug Use Investigation of Rivaroxaban in Pediatric Patients With Congenital Heart Disease (CHD) Who Had Undergone the Fontan Procedure.’ The study aims to assess the safety and effectiveness of rivaroxaban, an anticoagulant, in preventing blood clots in children with CHD post-Fontan surgery. This research is significant due to the limited data available, especially among Japanese patients, regarding the drug’s safety profile in this demographic.
Study Overview: Bayer AG is conducting an observational study titled An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer. The study aims to evaluate the safety and efficacy of darolutamide combined with androgen deprivation therapy (ADT) and docetaxel in Japanese men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC) during routine medical care. This research is significant as it seeks to enhance treatment strategies for this specific cancer type.
Bayer AG is currently conducting a Phase I clinical study titled Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors. The study aims to evaluate the safety and optimal dosage of a new drug, BAY3498264, when combined with sotorasib, in treating advanced solid cancers with KRASG12C mutations. This study is significant as it explores potential enhancements to existing cancer treatments.
Study Overview: Bayer AG is conducting an exploratory study titled Exploratory Study to Investigate the Association Between the Onset of Disseminated Intravascular Coagulation (DIC) and Disease Progression With Different Biomarker Candidates as Well as Standard Clinical and Demographic Parameters in Adult Patients With Sepsis. The study aims to understand how sepsis progresses to DIC by identifying biomarkers in patients admitted to intensive care units. This research is crucial as it addresses the limited treatment options for DIC in sepsis patients, particularly in the European population.
Bayer AG has initiated an observational study titled ‘An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A.’ The study aims to evaluate the effectiveness of damoctocog alfa pegol in preventing bleeding episodes in children aged 7 to under 12 years with hemophilia A, who have been previously treated with this or other FVIII products. This research is significant as it seeks to gather real-world data on the drug’s performance in routine medical practice.
Study Overview: Bayer AG is conducting a study titled FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting. The study aims to gather real-world data on the use of Finerenone, a drug prescribed for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The significance of this study lies in understanding treatment patterns and outcomes in routine medical care, providing valuable insights for healthcare providers and patients.
Study Overview: Bayer AG is conducting a Phase 3 clinical study titled A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. The study aims to assess the effectiveness and safety of aficamten in treating Japanese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition characterized by thickened heart muscles that impede blood flow.
Study Overview: Bayer AG is conducting a clinical study titled An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria. The study aims to evaluate the long-term safety and efficacy of finerenone, in combination with ACE inhibitors or angiotensin receptor blockers, in treating children and young adults with chronic kidney disease (CKD) and proteinuria. This research is significant as it seeks to improve treatment outcomes for a vulnerable population.
Study Overview: Bayer AG is conducting an observational study titled Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients, focusing on the safety of darolutamide in men with prostate cancer in Korea. The study aims to assess adverse events and the effectiveness of darolutamide, a drug prescribed for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), highlighting its significance in enhancing patient safety and treatment efficacy.
Study Overview: Bayer AG is conducting a Phase 3 study to evaluate the efficacy of darolutamide combined with androgen deprivation therapy (ADT) versus placebo with ADT in men with high-risk biochemical recurrence (BCR) of prostate cancer. The study aims to determine if this combination prolongs the time participants live without cancer progression or death compared to the placebo group, using advanced imaging techniques to monitor cancer spread.
Bayer AG, in collaboration with Janssen Research & Development, LLC, has initiated a study titled ‘Xarelto Paediatric VTE PASS Drug Utilization Study’ to observe the use and safety of Rivaroxaban in children under two years old with venous thromboembolism (VTE). This study aims to gather crucial data on the drug’s usage patterns and safety profile in this young demographic, where current information is limited.
Bayer AG is conducting a first-in-human study titled A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors. The study aims to assess the safety and effectiveness of BAY 3713372, a drug designed to target MTAP-deleted solid tumors by inhibiting the PRMT5 protein, potentially killing cancer cells while sparing normal cells.
Bayer AG is conducting a Phase 1 clinical study titled A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC). The study aims to assess the safety and efficacy of the drug BAY3546828 in treating advanced metastatic castration-resistant prostate cancer, a condition where prostate cancer spreads and resists standard hormone-lowering treatments.
Study Overview: Bayer AG is conducting a Phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard care for pediatric patients with heart failure and left ventricular systolic dysfunction (LVSD). This study aims to assess the long-term safety and efficacy of finerenone, a drug that may improve heart function by reducing inflammation and scarring.
Study Overview: Bayer AG is conducting a study titled Methodology Study in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass to Investigate Mechanisms Involved in Cardiac Surgery-associated Acute Kidney Injury. The study aims to understand how acute kidney injury develops in patients undergoing heart surgery with a heart-lung machine, focusing on identifying biomarkers that could lead to better prevention and treatment strategies.
Study Overview: Bayer AG is conducting a study titled ‘Special Drug Use Investigation for Eylea for Retinopathy of Prematurity (ROP)’ to gather data on the use of Eylea in Japanese infants with ROP, a condition where abnormal blood vessel growth in the retina can lead to blindness. The study aims to assess the safety and efficacy of Eylea in a real-world setting.
Bayer AG is currently conducting a clinical study titled ‘Drug Use Investigation for Eylea for Neovascular Glaucoma (NVG)’ to evaluate the safety and effectiveness of Aflibercept (Eylea) in Japanese patients diagnosed with Neovascular Glaucoma. This study is significant as it aims to provide real-world data on the use of Eylea, a treatment option for NVG, which could influence future clinical practices and patient outcomes.
Study Overview: Bayer AG is conducting an observational study titled ‘The SPECTRUM Study’ to evaluate the effectiveness of Aflibercept 8 mg in treating visual impairment due to neovascular age-related macular degeneration (nAMD) and diabetic macula edema (DME). The study aims to gather real-world data on the drug’s performance, focusing on changes in vision test scores over 12 months, which is crucial for understanding its practical benefits for patients with these conditions.
Study Overview: Bayer AG is conducting a Phase 3 study titled A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Efficacy, Safety, and PK/PD of Finerenone, in Addition to Standard-of-care, in Pediatric Patients, 6 Months to < 18 Years of Age With Heart Failure (HF) and Left Ventricular Systolic Dysfunction (LVSD). The study aims to assess the effectiveness and safety of finerenone in treating children with heart failure and LVSD, a condition that hinders the heart’s ability to pump blood effectively.
Bayer AG has initiated an observational study titled ‘Drug Utilization Study for Eylea 40 mg/mL Using the PICLEO Paediatric Dosing Device in Preterm Infants With Retinopathy of Prematurity in the UK.’ The study aims to collect data on the use of aflibercept (Eylea) in preterm infants with retinopathy of prematurity (ROP) using a pediatric dosing device. The primary objective is to determine the number of infants treated with this method and assess the feasibility of a long-term safety study.
Bayer AG, in collaboration with AskBio Inc, is embarking on a groundbreaking clinical study titled ‘Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA).’ The study aims to refine a new delivery method for AB-1005, targeting the brain’s putamen to enhance treatment efficiency for Parkinson’s Disease. The primary objectives are to streamline the procedure and ensure effective drug delivery, with safety and tolerability being key considerations.
Study Overview: Bayer AG, in collaboration with BlueRock Therapeutics, is conducting a Phase 3 study titled ‘exPDite-2’ to evaluate the efficacy and safety of bemdaneprocel, a midbrain dopaminergic neuronal cell therapy, in adults with Parkinson’s Disease (PD). This study aims to provide a novel treatment option for PD, potentially improving patient outcomes and quality of life.
Study Overview: Bayer AG is conducting a first-in-human Phase 1 study titled ‘A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC).’ The study aims to assess the safety and effectiveness of BAY 3547926, a new drug for advanced liver cancer, specifically targeting tumors with Glypican 3 (GPC3) protein. The significance lies in finding an optimal dose and understanding the drug’s absorption and distribution in the body.
Bayer AG is spearheading a promising clinical study titled ‘A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome.’ This study aims to assess the effectiveness of BAY 3401016 in slowing kidney function loss in adults with Alport Syndrome, a rare genetic disorder leading to kidney disease, hearing loss, and eye abnormalities.
Bayer AG is currently conducting an observational study titled A Multi-center, Two-arm, Open-label, Externally Controlled, Post-marketing Study of the Effectiveness and Safety of Vericiguat in HFrEF Patients in China. The study aims to evaluate the effectiveness and safety of Vericiguat in a real-world setting among Chinese patients with chronic heart failure with reduced ejection fraction (HFrEF). This research is significant as it seeks to provide insights beyond previous clinical trials by observing the drug’s performance under everyday conditions.
Study Overview: Bayer AG is conducting an observational study titled ‘OASIS PoST-Trial PAtient Registry (OASIS STAR)’ to explore the burden of vasomotor symptoms (VMS) and treatment patterns in menopausal women before and after participating in OASIS studies. The study aims to gather real-world data on prescription trends and healthcare resource utilization, providing insights into the impact of elizanetant, a drug for VMS, on these patterns.
Bayer AG is conducting an observational study titled ‘Post-marketing Surveillance Study for Verquvo (Vericiguat) in Korean Heart Failure Patients With Reduced Ejection Fraction.’ The study aims to gather real-world data on the safety and efficacy of Vericiguat in Korean patients with chronic heart failure with reduced ejection fraction (HFrEF). This condition affects the heart’s ability to pump blood effectively, leading to potential severe health complications.
Bayer AG is conducting a Phase 2 clinical study titled A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations. The study aims to assess the effectiveness and safety of sevabertinib (BAY2927088) in treating solid tumors with HER2 mutations, which are known to cause increased cancer cell growth. This research is significant as it could lead to new treatment options for various solid tumors.
Study Overview: Bayer AG is conducting a Phase 3 clinical trial titled A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations. The study aims to assess the effectiveness and safety of BAY 2927088, a new oral drug, compared to standard treatments for advanced NSCLC with HER2 mutations, a condition with limited treatment options.
Bayer AG is conducting a clinical study titled A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC). The study aims to assess the safety and efficacy of darolutamide, a drug that blocks androgens, in Indian patients with nmCRPC, a form of prostate cancer that progresses despite low testosterone levels.
Bayer AG is conducting an observational study titled ‘Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant.’ The study aims to assess the safety of nifurtimox, a drug used for over 50 years to treat Chagas disease, when administered during pregnancy. The primary focus is on understanding the risk of birth defects, pregnancy outcomes, and health issues in children up to 12 months old, as well as maternal complications.
Study Overview: Bayer AG is conducting an observational study titled ‘Vericiguat Drug Use Two-arm Investigation in Chronic Heart Failure’ to assess the safety of vericiguat in Japanese patients with chronic heart failure. The study aims to gather data on adverse events and cardiovascular outcomes when using vericiguat under real-world conditions, highlighting its significance in understanding the drug’s safety profile in a broader population.
Bayer AG is conducting a Phase 1 clinical study titled ‘A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)’. The study aims to assess the safety and effectiveness of 225Ac-PSMA-Trillium (BAY3563254), a promising treatment for mCRPC, a form of prostate cancer resistant to hormone therapy. This study is significant as it explores a new therapeutic avenue for a challenging cancer type.
Bayer AG is conducting a clinical study titled ‘A Single-blind, Placebo Controlled, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAY 3389934 Intravenous Infusions in Healthy Japanese Participants.’ The study aims to assess the safety and tolerability of BAY 3389934, an investigational drug developed for treating sepsis-associated disseminated intravascular coagulation (DIC). This research is crucial for the drug’s future development in Japan and potential treatment of septic DIC.
Study Overview: Bayer AG is conducting a clinical study titled A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria. The study aims to assess the effectiveness and safety of finerenone, a drug intended to improve kidney function in children with chronic kidney disease (CKD) and proteinuria, when used alongside existing treatments like ACE inhibitors or angiotensin receptor blockers.
Study Overview: Bayer AG is conducting an observational study titled ‘Finerenone Research of Outcomes and Drug Utilization’ (FINEROD) to assess the real-world use, safety, and efficacy of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This study is significant as it aims to gather data on the characteristics of patients using finerenone, a newly approved drug in the US, and its impact on kidney and heart health.
Study Overview: Bayer AG is conducting a post-marketing surveillance study titled ‘Post Marketing Surveillance Study for Jivi (Damoctocog Alfa Pegol) in Korean Patients With Hemophilia A.’ The study aims to assess the safety of damoctocog alfa pegol, a treatment for hemophilia A, in Korean patients who have previously used other treatments. This research is significant as it seeks to provide real-world safety data for a drug already approved for preventing or treating bleeding episodes in hemophilia A patients.
Bayer AG is conducting a study titled ‘Study in Participants With Mild to Moderate Arterial Hypertension to Investigate Safety and Tolerability of BAY3283142.’ The study aims to assess the safety and tolerability of the drug BAY3283142 in individuals with mild to moderate high blood pressure. This research is significant as it could pave the way for the drug’s development for treating chronic kidney disease (CKD), a condition where kidney function deteriorates over time.
Study Overview: Bayer AG is conducting a study titled An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies. The primary objective is to continue providing darolutamide treatment to patients who have previously participated in Bayer-supported studies, where ongoing treatment is deemed beneficial by their doctors. This study is significant as it aims to ensure continuity of care for cancer patients who have shown positive responses to darolutamide.
Study Overview: Bayer AG is conducting a non-interventional study titled ‘PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib.’ The study aims to assess the safety and effectiveness of VITRAKVI (larotrectinib) in patients with TRK fusion cancer, a condition where the NTRK gene fusion leads to tumor growth. This research is significant as it evaluates the drug’s real-world application in treating various cancers caused by this genetic fusion.
Bayer AG is conducting a clinical study titled ‘Special Drug Use Investigation for Larotrectinib,’ focusing on the treatment of NTRK gene fusion-positive advanced or recurrent solid tumors. The study aims to evaluate the safety and effectiveness of larotrectinib, a drug designed to inhibit TRK genes in cancer cells, thereby preventing cancer growth. This investigation is significant as it targets TRK fusion cancer, a rare condition caused by specific genetic changes.
Study Overview: Bayer AG, in collaboration with AskBio Inc, is conducting a Phase 2 clinical study titled ‘A Study of AAV2-GDNF in Adults With Moderate Parkinson’s Disease (REGENERATE-PD)’. The study aims to assess the safety and efficacy of AAV2-GDNF gene therapy delivered to the putamen in individuals with moderate Parkinson’s Disease. This research is significant as it explores a potential new treatment avenue for Parkinson’s, which could improve the quality of life for patients.
Study Overview: Bayer AG is conducting a Phase 1 study titled A Phase 1, Open-label, Single-dose Study to Assess the Influence of Hepatic Impairment on the Pharmacokinetics of BAY 2927088. The study aims to evaluate how moderate liver impairment affects the absorption, distribution, metabolism, and elimination of sevabertinib, a new cancer drug targeting HER2 mutations. This research is significant as it seeks to ensure the safe and effective use of sevabertinib in cancer patients with liver disease.
Study Overview: Bayer AG is conducting an observational study titled ‘SMART-Finder – Identification of Patients With Elevated UACR Levels in a T2DM Cohort.’ The study aims to identify patients with type 2 diabetes mellitus (T2DM) who have elevated urine-albumin-creatinine-ratio (UACR) levels, a marker for kidney damage, using the myTherapy app in Germany. This research is significant as it seeks to understand the prevalence and progression of kidney damage in T2DM patients, a critical complication that can lead to chronic kidney disease (CKD).
Bayer AG is conducting an observational study titled An Observational Study in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Following Treatment With Atezolizumab Plus Bevacizumab (AB) or With Another Approved Immuno-oncology Immune Checkpoint Inhibitor Combination in First-line. The study aims to gather data on the effectiveness of various treatments administered after initial therapy with Atezolizumab and Bevacizumab or similar drug combinations in adults with liver cancer that cannot be treated surgically. The significance lies in understanding the best sequence of treatments to enhance patient survival.
Study Overview: Bayer AG is conducting an observational study titled ‘ESTeeM: Evaluation of Sleep Disturbances in Menopause’ to explore how menopause affects women’s sleep and their current treatment methods. The study aims to understand the impact of menopause-related sleep disturbances on women’s quality of life and assess the need for new treatment options.
Bayer AG is currently conducting a clinical study titled A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of BAY 3018250 in Patients With Symptomatic Proximal Deep Vein Thrombosis. The study aims to evaluate the effectiveness and safety of BAY3018250, a drug designed to dissolve blood clots, in treating proximal deep vein thrombosis (DVT), a condition where clots form in the deep veins of the leg, potentially leading to severe health issues.
Study Overview: Bayer AG, in collaboration with Janssen Research & Development, LLC, is conducting an observational study titled ‘Xarelto Paediatric VTE PASS Drug Utilization Study.’ The study aims to evaluate the drug use patterns and safety of Rivaroxaban oral suspension in children under two years old with venous thromboembolism (VTE). This research is significant as it seeks to fill the gap in knowledge regarding the safety and efficacy of Rivaroxaban in this young demographic.
Study Overview: Bayer AG is conducting a Phase 3 study titled A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer. The study aims to evaluate whether the combination of darolutamide and ADT can extend the time patients live without cancer progression or death, compared to a placebo and ADT. This research is significant as it targets men with high-risk BCR of prostate cancer, a group with a higher likelihood of cancer spreading.
Bayer AG has launched a Phase 2 clinical study titled A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations. The study aims to assess the effectiveness and safety of sevabertinib (BAY2927088) in treating various solid tumors with HER2 mutations, excluding advanced non-small cell lung cancer. This research is significant as it explores potential new treatments for cancers characterized by HER2 mutations, which can lead to aggressive tumor growth.
Bayer AG is conducting an exploratory study titled ‘Exploratory Study to Investigate the Association Between the Onset of Disseminated Intravascular Coagulation (DIC) and Disease Progression With Different Biomarker Candidates as Well as Standard Clinical and Demographic Parameters in Adult Patients With Sepsis.’ The study aims to understand how sepsis progresses to DIC, a severe blood disorder, by identifying specific biomarkers in patients admitted to intensive care units across Europe. This research is significant as it seeks to enhance the understanding of DIC development in sepsis patients, potentially leading to improved treatment strategies.
Study Overview: Bayer AG is conducting a Phase I clinical study titled Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors. The study aims to evaluate the safety and maximum tolerable dose of BAY3498264 when combined with Sotorasib in treating advanced solid cancers with the KRASG12C mutation. This research is significant as it explores a potential enhancement of Sotorasib’s efficacy, which could lead to improved treatment outcomes for patients.
Bayer AG is conducting an observational study titled An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer. The study aims to evaluate the safety and efficacy of darolutamide combined with androgen deprivation therapy (ADT) and docetaxel in Japanese men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC). This research is significant as it seeks to enhance treatment decisions for this specific patient group.
Bayer AG has initiated a post-marketing surveillance study titled ‘Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients.’ The study aims to evaluate the safety of darolutamide, a treatment for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in Korean patients. This observational study is significant as it provides insights into the real-world safety profile of darolutamide, enhancing understanding of its effects in a specific population.
Study Overview: Bayer AG, in collaboration with Janssen Research & Development, LLC, is conducting an observational study titled Xarelto Paediatric VTE PASS Drug Utilization Study. This study aims to evaluate the usage patterns and safety of Rivaroxaban oral suspension in children under two years old diagnosed with venous thromboembolism (VTE). The study’s significance lies in its focus on a vulnerable pediatric population, where limited data currently exists regarding the drug’s safety and efficacy.
Bayer AG has initiated a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer. The study aims to determine if the combination of darolutamide and ADT can extend the time patients live without cancer progression or death compared to a placebo with ADT. This research is significant for men with high-risk BCR of prostate cancer, as it could lead to improved treatment strategies.
Study Overview: Bayer AG is conducting a Phase 2 open-label basket study titled A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations. The study aims to evaluate the efficacy and safety of BAY2927088 (sevabertinib) in treating solid tumors with HER2 mutations, excluding advanced non-small cell lung cancer, which could potentially provide a new treatment option for these patients.
Study Overview: Bayer AG is conducting a Phase 2 clinical study titled ‘A Single Arm, Open-label, Multicenter Phase 2 Study of Regorafenib in Participants Who Have Been Treated in a Previous Bayer-sponsored Regorafenib Study.’ The study aims to evaluate the safety and tolerance of continued regorafenib treatment in participants with solid tumors, who have previously participated in Bayer studies. This research is significant as it could provide insights into the long-term use of regorafenib, an anti-cancer drug, in managing solid tumors.
Study Overview: Bayer AG, in collaboration with AskBio Inc, is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson’s Disease. The study aims to evaluate the safety and efficacy of AAV2-GDNF gene therapy in treating moderate Parkinson’s Disease, highlighting its potential significance in advancing treatment options for this condition.
Study Overview: Bayer AG is conducting a study titled ‘SMART-Finder – Identification of Patients With Elevated UACR Levels in a T2DM Cohort.’ The study aims to identify individuals with type 2 diabetes mellitus (T2DM) who exhibit increased levels of albumin in their urine, a potential indicator of kidney damage. This research is significant as it seeks to understand the prevalence and progression of kidney-related complications in T2DM patients using the myTherapy app in Germany.
Bayer AG is conducting a first-in-human clinical study titled A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors. The study aims to assess the safety and optimal dosing of BAY 3713372, a drug targeting MTAP-deleted solid tumors by inhibiting PRMT5, potentially sparing normal cells while targeting cancerous ones.
The recent clinical study update from AstraZeneca and Bayer focuses on the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD5305 in combination with new hormonal agents for patients with metastatic prostate cancer. Officially titled ‘A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA),’ this study aims to explore innovative treatment options for a challenging condition.